egnite has launched the CardioCare Research Suite, an advanced component of its flagship platform, aimed at enhancing patient identification processes for cardiovascular clinical trials. This tool is ...

FELIQS has concluded a $9m Series A funding round, a significant step towards advancing the FLQ-101 clinical programme for ROP.

Pfizer's recent trial termination makes it yet another company facing challenges with CD47 studies in oncology.

Javara has formed a collaboration with Cape Fear Valley Health to enhance clinical trial access for patients in Fayetteville, North Carolina.

OpRegen is a suspension of embryonic stem cell-derived RPE cells restoring visual function in degenerative retinal pathologies.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

The endometriosis market is expected to grow from $938.0m in 2024 to $2.5 billion in 2034, at a compound annual growth rate ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Tango Therapeutics is focused on advancing precision medicine for cancer treatment. Credit: MacroEcon/Shutterstock. Tango Therapeutics has dosed the first subject in the Phase I/II trial assessing ...